Januvia Clears FDA; Sitagliptin Has “Neutral Effects” On Weight, Agency Says
Executive Summary
Merck's dipeptidyl peptidase IV inhibitor Januvia has no significant effect on weight, FDA said after approving sitagliptin for type 2 diabetes Oct. 16
You may also be interested in...
Expanded indications for Januvia
Merck's type 2 diabetes agent is approved as first-line therapy in combination with metformin and as an add-on to a sulfonylurea or sulfonylurea and metformin combination regimen, Merck says Oct. 17. Januvia (sitagliptin), the only marketed DPP-4 inhibitor, is indicated for improvement of glycemic control in adults with type 2 diabetes (1"The Pink Sheet" Oct. 23, 2006, p. 6). Labeling is also updated to include hypersensitivity reactions - including anaphylaxis, angioedema and exfoliative skin conditions - in the Warnings and Precautions sections...
Expanded indications for Januvia
Merck's type 2 diabetes agent is approved as first-line therapy in combination with metformin and as an add-on to a sulfonylurea or sulfonylurea and metformin combination regimen, Merck says Oct. 17. Januvia (sitagliptin), the only marketed DPP-4 inhibitor, is indicated for improvement of glycemic control in adults with type 2 diabetes (1"The Pink Sheet" Oct. 23, 2006, p. 6). Labeling is also updated to include hypersensitivity reactions - including anaphylaxis, angioedema and exfoliative skin conditions - in the Warnings and Precautions sections...
Roche Puts “Mind Towards” Phase III For CETP Inhibitor
Roche is leaning in favor of initiating a Phase III study of its cholesteryl ester transfer protein inhibitor, R1658, after conducting an in-depth analysis of data, evaluating information on Pfizer's failed torcetrapib and consulting experts